With the increasing number of medications based on marijuana, it isn't surprising that the interest in this stocks is constantly growing, especially on the background of less restrictive regulations. Given this fact, marijuana stocks seem a promising investment.
Among the leaders are clearly Aphria, Corbus Pharmaceutical, Canopy Growth Corporation, Naturewell, GW Pharmaceuticals and so on. But in order to decide which one is a burden at the moment, or which of these is undermined, we must analyse the current situation.
Starting with Corbus Pharmaceutical, after receiving approval to broaden Phase 2 of a clinical study, during the last quarter of 2016, their cannabinoid drug Resunab was proved to have high efficacy and 0% placebo effect. As a medicine against systemic sclerosis, the demand is extremely high and can deprecate the skeptics of this stock. After a recent downfall, the current valuation, according to NASDAQ, is 8,75. To summarize, reduced price and a statistically promising future guarantees Corbus a place in my portfolio.
Proceeding to safe mode, GW Pharmaceuticals is generally known as a secure stock for 2017. Most of the well-known investors claim that the chance of GW’s valuation to increase is almost 100%. The two most powerful releases are Syndros (a form of Dronabinol) and Epidiolex, the second one still waiting for FDA approval.
Finally, what marijuana stocks are likely to soar in 2017? Which are the most promising ones from your vantage point?